<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36930042</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1941-837X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Journal of medical economics</Title><ISOAbbreviation>J Med Econ</ISOAbbreviation></Journal><ArticleTitle>Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving <i>reldesemtiv</i> or placebo in FORTITUDE-ALS.</ArticleTitle><Pagination><StartPage>488</StartPage><EndPage>493</EndPage><MedlinePgn>488-493</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/13696998.2023.2192588</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="UNASSIGNED">To estimate the health utilities and quality-adjusted life years (QALYs) in patients with amyotrophic lateral sclerosis (ALS) receiving <i>reldesemtiv</i> versus placebo in FORTITUDE-ALS.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">We performed a post hoc analysis of clinical trial data from FORTITUDE-ALS (NCT03160898). This Phase IIb, double-blind, randomized, dose-ranging, placebo-controlled, parallel-group, 12-week trial evaluated <i>reldesemtiv</i> in patients with ALS. Health utilities from the five-level version of the EuroQol five-dimensional questionnaire (EQ-5D-5L) were estimated using ALS Functional Rating Scale-Revised (ALSFRS-R) scores collected during the trial. QALYs were estimated using the area under the curve method.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The full analysis set consisted of 456 patients (<i>reldesemtiv n</i>&#x2009;=&#x2009;342, placebo <i>n</i>&#x2009;=&#x2009;114), who received at least one dose of the double-blind study drug, and had ALSFRS-R assessed at baseline and at least one post-baseline assessment. The difference in EQ-5D-5L utility least-squares (LS) mean change from baseline to week 12 for <i>reldesemtiv</i> versus placebo, adjusted for baseline values, was statistically significant (0.03, 95% confidence interval [CI]: 0.01, 0.05; <i>p</i> = .0008). The incremental QALY of <i>reldesemtiv</i> versus placebo adjusted for baseline utility values showed a modest, but statistically significant, difference (0.004, 95% CI: 0.001, 0.007; <i>p</i> = .0058).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">This post hoc analysis of FORTITUDE-ALS suggests that <i>reldesemtiv</i> showed a modest but significant benefit in health utilities and QALYs compared with placebo. Future long-term studies that include direct collection of EQ-5D-5L data will be needed to confirm our findings.</AbstractText><AbstractText Label="CLINICALTRIALS.GOV IDENTIFIER" NlmCategory="UNASSIGNED">NCT03160898.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gebrehiwet</LastName><ForeName>Paulos</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-7692-2189</Identifier><AffiliationInfo><Affiliation>Cytokinetics, Incorporated, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cytokinetics, Incorporated, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudnicki</LastName><ForeName>Stacy A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0002-3499-5208</Identifier><AffiliationInfo><Affiliation>Cytokinetics, Incorporated, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarocco</LastName><ForeName>Phil</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cytokinetics, Incorporated, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Jenny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cytokinetics, Incorporated, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolff</LastName><ForeName>Andrew A</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0002-9094-0359</Identifier><AffiliationInfo><Affiliation>Cytokinetics, Incorporated, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butzner</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6015-7910</Identifier><AffiliationInfo><Affiliation>Cytokinetics, Incorporated, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9579-5341</Identifier><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrews</LastName><ForeName>Jinsy A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-3474-7140</Identifier><AffiliationInfo><Affiliation>The Neurological Institute of New York, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genge</LastName><ForeName>Angela</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5587-9946</Identifier><AffiliationInfo><Affiliation>Clinical Research Unit, Montreal Neurological Institute-Hospital, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>Dyfrig A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0001-8247-7459</Identifier><AffiliationInfo><Affiliation>Centre for Health Economics &amp; Medicines Evaluation, School of Medical and Health Sciences, Bangor University, Bangor, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Carlayne E</ForeName><Initials>CE</Initials><Identifier Source="ORCID">0000-0002-9368-395X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Texas Health Science Center at San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lechtzin</LastName><ForeName>Noah</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-9088-8749</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Timothy M</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0002-3424-5511</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shefner</LastName><ForeName>Jeremy M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0001-5067-5602</Identifier><AffiliationInfo><Affiliation>Barrow Neurological Institute, University of Arizona, Phoenix, AZ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Creighton University, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Med Econ</MedlineTA><NlmUniqueID>9892255</NlmUniqueID><ISSNLinking>1369-6998</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4S0HBYW6QE</RegistryNumber><NameOfSubstance UI="C000722562">reldesemtiv</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019057" MajorTopicYN="N">Quality-Adjusted Life Years</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">EQ-5D-5L</Keyword><Keyword MajorTopicYN="N">I</Keyword><Keyword MajorTopicYN="N">I1</Keyword><Keyword MajorTopicYN="N">I10</Keyword><Keyword MajorTopicYN="N">I19</Keyword><Keyword MajorTopicYN="N">Randomized clinical trial</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">health utilities</Keyword><Keyword MajorTopicYN="N">reldesemtiv</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>17</Day><Hour>11</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36930042</ArticleId><ArticleId IdType="doi">10.1080/13696998.2023.2192588</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>